Skip to main content
KPTI logo

Karyopharm Therapeutics Inc. (KPTI) Stock Analysis

DELISTED

What happened to Karyopharm Therapeutics Inc. (KPTI) stock?

Karyopharm Therapeutics Inc. (KPTI) no longer trades on public markets. The figures below are historical and are not a current quote.

Status:
Delisted — no longer trades
Vol: 8.28M| Target: $7.33 (Stored FMP targets · Captured Nov 18, 2026) (estimate, not advice)|
Data from FMP · Methodology

For informational purposes only. Not financial advice. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR

Karyopharm Therapeutics Inc. (KPTI). Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company focused on discovering, developing, and commercializing drugs for the treatment of cancer and other diseases.

Last analyzed: May 10, 2026
Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company focused on discovering, developing, and commercializing drugs for the treatment of cancer and other diseases. Their lead compound, XPOVIO, is approved for multiple myeloma and diffuse large B-cell lymphoma.

Karyopharm Therapeutics Inc. (KPTI) Healthcare & Pipeline Overview

Employees228
Model self-rating on this text: 81% (not a measure of the evidence) Updated: May 10, 2026

More about this archive record

Can I still buy KPTI shares?

No. KPTI stopped trading on public markets, so the shares are not available through a broker. Anything you see quoted for KPTI elsewhere is historical data, not a live market.

Are the figures on this page current?

No. Every number here is the last value recorded before KPTI stopped trading. Nothing on this page updates, and none of it is a current quote.

Why does this page still exist?

Because people still search for what happened to Karyopharm Therapeutics Inc.. An archived profile that states the delisting plainly is more useful than a dead link — provided it is labelled as history, which is what this page does.

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources

Analysis updated
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. Last updated: .

Data provided for informational purposes only.